Summit Therapeu ADR (SMMT) Stock Price, Quote & News

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry: Biotechnology

Sector: Healthcare

Phone: 305 203 2034

Website: www.smmttx.com

Address:

601 Brickell Key Drive, Suite 1000, Miami, United States

SmokeWagon Mar. 6 at 5:08 PM

$SMMT !!!

0 · Reply

CoyoteUgly Mar. 6 at 3:35 PM

$SMMT

0 · Reply

TruthBroker2 Mar. 6 at 3:19 PM

$SMMT Team Summit 20

0 · Reply

DragonAlgo Mar. 6 at 2:51 PM

🐉 $SMMT CALL — DragonAlgo® Signal Contract: SMMT CALL Expiry: 2026-03-06 | Strike: $18.00 | Type: CALL Option Plan (premium): Entry: $0.07 Stop: $0.05 TP1: $0.09 TP2: $0.12 TP3: $0.17 🔗 https://dragonalgo.com

0 · Reply

TruthBroker2 Mar. 6 at 1:40 AM

$SMMT

0 · Reply

40persense Mar. 6 at 1:33 AM

$SMMT I no longer trade this stock . I don’t know what’s going on fundamentally, but it looks like a good one to put on bearish option strategies with break even above $19 and take profits 25% - 50% .

0 · Reply

LadsAndGents Mar. 5 at 7:26 PM

$SMMT can we close back into $15

0 · Reply

TruthBroker2 Mar. 5 at 5:26 PM

$SMMT

0 · Reply

db59 Mar. 5 at 4:45 PM

$SMMT Summit dipped below $15 on algorithmic response over war headlines—even while fundamentals remain untouched, and even in anticipation of a number of highly significant catalysts throughout the year. Smart money loads up long while algorithms react reflexively to headlines.

0 · Reply

letstalk8 Mar. 5 at 3:04 PM

$SMMT Looks like another day to buy more sub $15.00 love adding here lets go!!!

0 · Reply

Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Feb 26, 2026, 6:45 PM EST - 8 days ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Feb 24, 2026, 3:54 AM EST - 10 days ago

Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript

Feb 23, 2026, 4:05 PM EST - 11 days ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

Feb 17, 2026, 5:05 PM EST - 17 days ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Jan 30, 2026, 4:30 PM EST - 5 weeks ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 29, 2026, 7:30 AM EST - 5 weeks ago

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Jan 12, 2026, 3:56 PM EST - 7 weeks ago

Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 6:15 AM EST - 7 weeks ago

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

GSK

Jan 12, 2026, 6:00 AM EST - 7 weeks ago

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Jan 6, 2026, 7:30 AM EST - 2 months ago

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 9:43 PM EST - 3 months ago

Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 5:13 PM EST - 3 months ago

Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 19, 2025, 4:26 AM EST - 3 months ago

Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying

Nov 18, 2025, 12:38 PM EST - 3 months ago

Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 11, 2025, 4:11 AM EST - 4 months ago

Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 9:00 AM EST - 4 months ago

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Oct 31, 2025, 7:00 AM EDT - 4 months ago

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Oct 22, 2025, 8:00 AM EDT - 4 months ago

Summit Therapeutics Raises $500 Million in Private Placement

Oct 20, 2025, 5:05 PM EDT - 4 months ago

Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript

Oct 20, 2025, 2:35 PM EDT - 4 months ago

Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold

Oct 20, 2025, 10:05 AM EDT - 4 months ago

What's Going On With Summit Therapeutics Stock On Monday?

Oct 20, 2025, 6:45 AM EDT - 4 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Oct 19, 2025, 10:30 AM EDT - 4 months ago

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Oct 17, 2025, 7:00 AM EDT - 5 months ago

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Oct 15, 2025, 7:00 AM EDT - 5 months ago

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Sep 24, 2025, 7:00 AM EDT - 5 months ago

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Sep 22, 2025, 2:45 PM EDT - 5 months ago

Ten Bull Market 10-Baggers

APP CVNA FTAI HOOD MSTR NVDA PLTR

Sep 17, 2025, 10:54 PM EDT - 6 months ago

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 16, 2025, 4:31 PM EDT - 6 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 6 months ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 9, 2025, 9:12 AM EDT - 6 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

LNAI

Sep 8, 2025, 3:36 PM EDT - 6 months ago

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Sep 8, 2025, 8:28 AM EDT - 6 months ago

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Sep 8, 2025, 8:10 AM EDT - 6 months ago

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

NFE

Sep 7, 2025, 6:08 AM EDT - 6 months ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 3:30 AM EDT - 6 months ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 3, 2025, 7:00 AM EDT - 6 months ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Aug 27, 2025, 2:43 PM EDT - 6 months ago

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Aug 14, 2025, 7:00 AM EDT - 7 months ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 11, 2025, 5:03 PM EDT - 7 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Jul 14, 2025, 3:00 PM EDT - 8 months ago

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 4, 2025, 5:10 AM EDT - 8 months ago

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

AZN

Jun 30, 2025, 8:00 AM EDT - 8 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Jun 5, 2025, 8:00 AM EDT - 9 months ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 2:52 PM EDT - 9 months ago

Summit Therapeutics: Market Overreaction Creates Opportunity

SmokeWagon Mar. 6 at 5:08 PM

$SMMT !!!

0 · Reply

CoyoteUgly Mar. 6 at 3:35 PM

$SMMT

0 · Reply

TruthBroker2 Mar. 6 at 3:19 PM

$SMMT Team Summit 20

0 · Reply

DragonAlgo Mar. 6 at 2:51 PM

0 · Reply

TruthBroker2 Mar. 6 at 1:40 AM

$SMMT

0 · Reply

40persense Mar. 6 at 1:33 AM

0 · Reply

LadsAndGents Mar. 5 at 7:26 PM

$SMMT can we close back into $15

0 · Reply

TruthBroker2 Mar. 5 at 5:26 PM

$SMMT

0 · Reply

db59 Mar. 5 at 4:45 PM

0 · Reply

letstalk8 Mar. 5 at 3:04 PM

$SMMT Looks like another day to buy more sub $15.00 love adding here lets go!!!

0 · Reply

TruthBroker2 Mar. 4 at 10:06 PM

$SMMT

0 · Reply

BobBijawklah Mar. 4 at 6:35 PM

$IBRX I have some hot Picks folks Leading or best in class. IBRX below 9 is a buy. $SMMT will be the next iteration of pdl1 surpassing keytruda in all indications PT $35 PDUFA Nov 2026. $DNLI hunter syndrome PDUFA April 2026 PT 30 .$ACAD nuplazid and dayblue 1 billion in revenue . Remlifanserin data due out later this year. Potential revenue of Remlifanserin 4 billion. PT 35. $MLTX Merck already put a 41 dollar offer which was turned down. Trades at 18 per share PT 40.

2 · Reply

LeisureSuitLarry Mar. 4 at 6:22 PM

$SMMT

0 · Reply

TruthBroker2 Mar. 4 at 4:36 PM

$SMMT

0 · Reply

SellasgpsDormantBAT9 Mar. 4 at 3:54 PM

$CAPR $RVMD $SLS $SMMT I expect 1st Sellas trading T1 halt over $7.09+ ✌️🙏❤️‍🩹

0 · Reply

letstalk8 Mar. 4 at 3:18 PM

$SMMT I am buying today picked up a few sub $15! love it lets go!!

0 · Reply

SellasgpsDormantBAT9 Mar. 4 at 3:12 PM

$CAPR $RVMD $SLS $SMMT Good Dr. Angelos Stergiou Overwhelming Paradigm shifting Linkedln posts have stopped in preparation of the Binary Catalyst PR. Sellas BOD has 2 business days to PR after accepting a written offer. ✌️🙏❤️‍🩹

0 · Reply

SellasgpsDormantBAT9 Mar. 4 at 2:31 PM

$CAPR $RVMD $SLS $SMMT SLS 1st trading halt at $7.09. ✌️🙏❤️‍🩹

0 · Reply

TruthBroker2 Mar. 4 at 1:09 PM

$SMMT

0 · Reply

SellasgpsDormantBAT9 Mar. 4 at 1:08 PM

$CAPR $RVMD $SLS $SMMT Keep an eye out for SLS Nasdaq T1 Halt Schedule. 1st open after halt $60.00- $120.00+ 🙏☝️✌️❤️‍🩹

0 · Reply

SellasgpsDormantBAT9 Mar. 4 at 12:23 PM

$RVMD $SLS $SMMT $CAPR I wanted to Thank again CAPR Shareholder that sold me CAPR shares Pre market on 12/3/25 👇 at $4.25 half an hour before the halt. I resold those shares after the halt was lifted at $40.22. I put the sell order at SELL @38.77 LMT but it opened at $40.22 . Now that's how Binary Catalyst Stocks work. GPS Regal Pivotal Registrational phase 3 results will shake up the entire Oncology/Hematology sector and BO shortly thereafter = $120.00+👇 ✌️❤️‍🩹👏

0 · Reply

SellasgpsDormantBAT9 Mar. 4 at 12:04 PM

$RVMD $SLS $SMMT My Long Brothers and Sisters follow the following trading halt schedule in the coming hours and days: 1st trading halt $60.00- $100.00+ 2nd Trading Halt= $100- $150.00+ 3rd Trading Halt= $180.00- $220.00+ See you all on the other side. ✌️🙏❤️‍🩹👏

1 · Reply

Market Cap	11.58B
Revenue (ttm)	0.00
Net Income (ttm)	-1.08B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,307,400
Avg Vol	2,573,628
Day's Range	N/A - N/A
Shares Out	775.37M
Stochastic %K	23%
Beta	-1.43
Analysts	Strong Sell
Price Target	$31.71